<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029104</url>
  </required_header>
  <id_info>
    <org_study_id>CXL-005</org_study_id>
    <nct_id>NCT03029104</nct_id>
  </id_info>
  <brief_title>Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas</brief_title>
  <official_title>Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cxlusa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cxlusa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess changes in visual acuity and corneal symmetry after corneal collagen
      cross-linking (CXL) of asymmetric corneas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with
      conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid
      marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation
      post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all
      patients receive treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sufficient clinical results obtained to support study endpoints.
  </why_stopped>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Visual acuity will be evaluated by an observer who is masked as to the treatment protocol to which study subjects have been assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected Distance Visual Acuity (CDVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in corrected distance visual acuity (CDVA) compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity (UCVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in uncorrected distance visual acuity (UCVA) compared to baseline
Secondary: Change at 6 months as compared to baseline in:
Uncorrected distance visual acuity
KMax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KMax</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Kmax compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2228</enrollment>
  <condition>Keratoconus</condition>
  <condition>Corneal Diseases</condition>
  <condition>Eye Diseases</condition>
  <condition>Photosensitizing Agents</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CXLO Corneal Strengthening Solution and UVA Illumination Device</intervention_name>
    <description>CXLO Corneal Strengthening Solution</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of at least one of the following conditions:

               1. Keratoconus

               2. Forme fruste keratoconus

               3. Post-LASIK ectasia

               4. Pellucid marginal degeneration

               5. Forme fruste pellucid marginal degeneration

               6. Diurnal fluctuation post-radial keratotomy

               7. Terrien's marginal degeneration

        Exclusion Criteria:

          1. Corneal thickness &lt; 375 microns measured by ultrasound or Pentacam.

          2. Contraindications or hypersensitivities to any study medications or their components.

          3. Pregnancy or breastfeeding.

          4. Any history of herpes simplex corneal disease in an eye to be treated.

          5. Nystagmus or any other condition that would, in the judgement of the investigator,
             prevent a steady gaze during the treatment.

          6. Inability to cooperate with diagnostic tests.

          7. Enrollment in another ophthalmic clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg J Berdy, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmology Associates, St. Louis, MO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schwartz Laser Eye Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodman Eye Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornea Consultants of Colorado</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120-4508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants, Ltd.</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornea Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Forme fruste keratoconus</keyword>
  <keyword>Post-LASIK ectasia</keyword>
  <keyword>Pellucid marginal degeneration</keyword>
  <keyword>Forme fruste pellucid marginal degeneration</keyword>
  <keyword>Diurnal fluctuation post-radial keratotomy</keyword>
  <keyword>Terrien's marginal degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

